Literature DB >> 18621428

Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin.

Volker Rudat1, Hans Eckel, Peter Volling, Michael Schröder, Susanne Staar, Frank Wallner, Michael Wannenmacher, Andreas Dietz.   

Abstract

PURPOSE: This prospective phase II study was undertaken to assess the feasibility of a larynx preservation protocol with simultaneous radiochemotherapy. PATIENTS AND METHODS: Between 3/1998 and 10/2000, 42 patients with moderately advanced cancer of the larynx (n=25) and hypopharynx (n=17) eligible for total laryngectomy (LE) were treated in a prospective larynx preservation study. The study protocol scheduled 66Gy in 5 weeks using a concomitant boost technique and 70mg/m(2) Carboplatin on days 1-5 in weeks 1 and 5.
RESULTS: The median follow-up time of the censored study patients was 41 months (9-95 months). The 5-year overall survival was 0.66 (95% CI 0.48-0.84), the 5-year laryngectomy-free survival 0.60 (95% CI 0.42-0.78), and the laryngeal preservation rate at 5 years 0.67 (95% CI 0.49-0.85). Cox multivariate regression analysis showed the total tumor volume to be the only statistically significant factor on locoregional failure-free survival. Six of 23 tumor-free long-term survivors received a tracheotomy because of late laryngeal toxicity associated with dysphagia 30-79 months after radiochemotherapy.
CONCLUSIONS: Due to the late laryngeal toxicity observed the value of this regimen for larynx preservation is limited.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621428     DOI: 10.1016/j.radonc.2008.06.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  [Multimodal laryngeal preservation: current data-based opinion].

Authors:  A Dietz; A Boehm; G Wichmann; D Niederwieser; S Dietzsch; M Fuchs
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

2.  [Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma].

Authors:  H E Eckel
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

3.  Laryngeal sensation and pharyngeal delay time after (chemo)radiotherapy.

Authors:  Takashi Maruo; Yasushi Fujimoto; Kikuko Ozawa; Mariko Hiramatsu; Atsushi Suzuki; Naoki Nishio; Tsutomu Nakashima
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-23       Impact factor: 2.503

Review 4.  Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review.

Authors:  Xiao-Ning Luo; Liang-Si Chen; Si-Yi Zhang; Zhong-Ming Lu; Yan Huang
Journal:  Radiol Med       Date:  2015-05-16       Impact factor: 3.469

5.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

6.  Definitive Radiotherapy versus Postoperative Radiotherapy of Patients with Oro- and Hypopharyngeal Cancer: Impact of Prognostic Factors.

Authors:  Volker Rudat; Salia Ahmet-Osman; Oliver Schramm; Andreas Dietz
Journal:  J Oncol       Date:  2012-01-18       Impact factor: 4.375

7.  Changes in laryngeal sensation evaluated with a new method before and after radiotherapy.

Authors:  Kikuko Ozawa; Yasushi Fujimoto; Tsutomu Nakashima
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-08-25       Impact factor: 2.503

8.  Systemic therapy strategies for head-neck carcinomas: Current status.

Authors:  Thomas K Hoffmann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

9.  Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences.

Authors:  Andreas Dietz; Gunnar Wichmann
Journal:  EPMA J       Date:  2011-05-14       Impact factor: 6.543

10.  Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients.

Authors:  Gerhard Dyckhoff; Rolf Warta; Christel Herold-Mende; Elisabeth Rudolph; Peter K Plinkert; Heribert Ramroth
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.